Navigation Links
Data on VIVUS' Qnexa To Be Presented During Two Podium Presentations at ADA Annual Meeting
Date:6/2/2009

ased on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2008 and periodic reports filed with the Securities and Exchange Commission.

CONTACT:

    VIVUS, Inc.

    Timothy E. Morris
    Chief Financial Officer
    650-934-5200


    Investor Relations:  The Trout Group
                         Brian Korb
                         646-378-2923

    Public Relations:    Pure Communications, Inc.
                         Jennifer Torres
                         312-624-9802


'/>"/>
SOURCE VIVUS, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. VIVUS Reports First Quarter 2009 Financial Results and Highlights
2. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
3. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
4. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
5. Results of Colon Cancer Study Utilizing Pressure Cycling Technology (PCT) Presented at the American College of Gastroenterology Annual Scientific Meeting
6. Kuvan, Naglazyme and Aldurazyme Data to Be Presented at the 57th Annual Meeting of the American Society of Human Genetics
7. Micromet Data Presented at the International AACR-NCI-EORTC Conference Support the Development of Adecatumumab (MT201) in Earlier Stage Cancer Disease Settings
8. Three PDX (Pralatrexate) Studies Presented at the 2007 AACR-NCI-EORTC Conference
9. Salugens Award-Winning Research on Using DNA Information to Customize Nutritional Supplementation for Weight Loss Presented at the Second Annual Bruce Ames International Symposium on Nutritional Genomics at the University of California, Davis
10. Reverse Cholesterol Transport by RVX-208 a Small Molecule for ApoA-I Production Increase Presented at American Heart Association Scientific Meeting
11. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... ... June 30, 2015 , ... ... She has accepted the position of vice president of instruction at Chippewa Valley ... , “I greatly appreciated the opportunity to lead SIUE during the past three ...
(Date:6/29/2015)... Pharnext SAS today announced that data related to its ... Type 1A (CMT1A), is being presented in four posters and ... Biennial Meeting at the Quebec Congress Center in ... 2015. At Poster Viewing Session 4, four posters ... EDT: Poster 23: "A Meta-Analysis Of Randomized ...
(Date:6/29/2015)...  AACC, a global scientific and medical professional ... is pleased to announce that the impact factor ... increased to 7.9 in the 2014 Thomson Reuters ... Chemistry in the top 3% of all ... the research it publishes on laboratory medicine and ...
(Date:6/29/2015)... St. Louis, MO (PRWEB) , ... June 29, 2015 , ... ... July 15 – July 16 and for the fourth year in a row, will ... on what changes are taking place at the intersection of data and technology. The ...
Breaking Biology Technology:SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 2SIUE’s Furst-Bowe Accepts VP of Instruction at CVTC 3Pharnext's PXT-3003 Featured in Multiple Presentations at 2015 Peripheral Nerve Society Biennial Meeting 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3
... Imago MADISON, Wis. Mass storage vendor ... Imago Scientific Instruments to meet the manufacturing challenges ... that Seagate has adopted Imago's LEAP Microscope to provide ... magnetic heads and media. , ,According to the company, ...
... RFID tag MADISON, Wis. A new RFID ... advance showing September 29 to attendees of the its ... is holding its seventh annual E-Business Best Practices ... , ,RFID, which involves tagging products or shipments with ...
... BROOKFIELD, Wis. Fiserv Imagesoft , a ... on Thursday that it has completed enhancement of its ... toward improving the security of image replacement documents (IRDs), ... an original check. , ,The new features of ExchangeGuard ...
Cached Biology Technology:E-business conference to give sneak peek into university RFID laboratory 2
(Date:6/16/2015)... Sweden , June 16, 2015 ... all touch fingerprint sensors in the company,s portfolio from one ... Deliveries are planned to mainly take place during the third ... in Asia . Jörgen Lantto, ... evidence of    the   growing interest from smartphone OEMs ...
(Date:6/15/2015)... According to a new market research report ... Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) ... Natural Language Processing Market is expected to grow to ... forecast period 2015-2020. Browse 65 market ...   through 155 P ages and in-depth TOC ...
(Date:6/15/2015)... 15, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... growing mobile commerce market, announces that its leading payment security ... at Digital Experience! @ NYC June 18th. Digital ... latest innovation in technology to over 300 of the top ... the Metropolitan Pavilion in New York City ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 375 MSEK 2Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 5Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 2Wocket Smart Wallet Exhibiting at Pepcom Digital Experience! @ NYC June 18th 3
... 2011 GNS Healthcare, Inc. (GNS) is ... lung cancer research with a supercomputing platform that can ... assembled from imaging, genetics, pathology, and other areas. The ... a given treatment. GNS will analyze NCI ...
... TORONTO, Ont., July 12, 2001--Eating nuts every day could ... according to new research from St. Michael,s Hospital and ... online by the journal Diabetes Care , a ... of Toronto Department of Nutritional Sciences; St. Michael,s Hospital ...
... 07/07/11, Clearwater Beach, FL. Research to be presented at ... of Ingestive Behavior (SSIB), the foremost society for research into ... a naturally occurring gut hormone, increases our willingness to pay ... non-food items. Have you ever wondered about why you ...
Cached Biology News:GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients 2GNS Healthcare Collaborates with NCI in New Approach to Lung Cancer; Supercomputer Analysis to Aid in Matching Targeted Drugs to Patients 3A 'nutty' solution to type 2 diabetes management 2